Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1995 2
1996 2
1997 3
1998 8
1999 15
2000 32
2001 17
2002 19
2003 17
2004 11
2005 17
2006 20
2007 19
2008 23
2009 22
2010 23
2011 21
2012 21
2013 20
2014 17
2015 25
2016 12
2017 14
2018 16
2019 12
2020 10
2021 11
2022 7
2023 16
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.
Morimoto S, Takahashi S, Ito D, Daté Y, Okada K, Kato C, Nakamura S, Ozawa F, Chyi CM, Nishiyama A, Suzuki N, Fujimori K, Kondo T, Takao M, Hirai M, Kabe Y, Suematsu M, Jinzaki M, Aoki M, Fujiki Y, Sato Y, Suzuki N, Nakahara J; Pooled Resource Open-Access ALS Clinical Trials Consortium; Okano H. Morimoto S, et al. Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Free article. Clinical Trial.
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole or placebo for 24 weeks in the double-blind period to evaluate safety, tolerability, and therapeutic effects. ...However, in the op …
iPSC-based drug discovery led to a phase 1/2a trial of ropinirole in ALS. 20 participants with sporadic ALS received ropinirole …
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler OS, Oztekin N, Oztekin MF. Gencler OS, et al. Ideggyogy Sz. 2022 Jan 30;75(1-02):39-49. doi: 10.18071/isz.75.0039. Ideggyogy Sz. 2022. PMID: 35112520 Free article. Clinical Trial. English.
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. ...In the pramipexole subgroup …
Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropini …
Ropinirole, a non-ergoline dopamine agonist.
Jost WH, Angersbach D. Jost WH, et al. CNS Drug Rev. 2005 Autumn;11(3):253-72. doi: 10.1111/j.1527-3458.2005.tb00046.x. CNS Drug Rev. 2005. PMID: 16389293 Free PMC article. Review.
This review article provides a closer look at the experimental and clinical studies with ropinirole published so far. Ropinirole is a non-ergoline dopamine agonist which has been proven to be effective in both, monotherapy and combination therapy of idiopathic Parki …
This review article provides a closer look at the experimental and clinical studies with ropinirole published so far. Ropinirole …
Clinical pharmacokinetics of ropinirole.
Kaye CM, Nicholls B. Kaye CM, et al. Clin Pharmacokinet. 2000 Oct;39(4):243-54. doi: 10.2165/00003088-200039040-00001. Clin Pharmacokinet. 2000. PMID: 11069211 Review.
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. ...There is no obvious plasma concentration-effect relationship for ropinirole....
Ropinirole is a selective non-ergoline dopamine D2 receptor agonist indicated for use in treating Parkinson's disease. ...There is no …
Ropinirole treatment for restless legs syndrome.
Chitnis S. Chitnis S. Expert Opin Drug Metab Toxicol. 2008 May;4(5):655-64. doi: 10.1517/17425255.4.5.655. Expert Opin Drug Metab Toxicol. 2008. PMID: 18484922 Review.
Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on objective measures of RLS motor symptoms, such as periodic leg movements; and on subjective measures of sleep, ropinirole was genera …
Significant improvements in RLS symptoms were observed within 2 nights of treatment. Ropinirole also produced significant benefits on …
Ropinirole: current status of the studies.
Jost WH. Jost WH. J Neurol. 2004 Sep;251 Suppl 6:VI/13-8. doi: 10.1007/s00415-004-1604-8. J Neurol. 2004. PMID: 15675719 Review.
Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination therapy against idiopathic Parkinson's disease. ...A neuroprotective effect is under discussion. In addition to Parkinson's disease, ropiniro …
Ropinirole is a modern, non-ergoline dopamine agonist which has been shown to be effective as monotherapy as well as combination ther …
Drug safety evaluation of ropinirole prolonged release.
Stocchi F, Radicati FG, Torti M. Stocchi F, et al. Expert Opin Drug Saf. 2014 Mar;13(3):383-9. doi: 10.1517/14740338.2014.870152. Epub 2014 Feb 3. Expert Opin Drug Saf. 2014. PMID: 24490799 Review.
INTRODUCTION: The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine agonists in the treatment of early Parkinson's disease. To avoid these problems, Ropinirole prolonged release (RPR), a non-ergoline …
INTRODUCTION: The need for multiple administrations and a difficult titration schedule has always represented a limit in the use of dopamine …
A review of ropinirole prolonged release in Parkinson's disease.
Nashatizadeh MM, Lyons KE, Pahwa R. Nashatizadeh MM, et al. Clin Interv Aging. 2009;4:179-86. doi: 10.2147/cia.s3358. Epub 2009 May 14. Clin Interv Aging. 2009. PMID: 19503779 Free PMC article. Review.
Patients on ropinirole prolonged release were also more likely to require less daily levodopa. Ropinirole prolonged release is well tolerated with a similar adverse effect profile to other non-ergot dopamine agonists. The most common adverse effects …
Patients on ropinirole prolonged release were also more likely to require less daily levodopa. Ropinirole prolonged release is …
Ropinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
Heneghan LJ, Tsang A, Dimino C, Khandji AG, Panigrahi SK, Page-Wilson G. Heneghan LJ, et al. J Clin Endocrinol Metab. 2024 Jan 18;109(2):e667-e674. doi: 10.1210/clinem/dgad545. J Clin Endocrinol Metab. 2024. PMID: 37715962 Free PMC article. Clinical Trial.
Ropinirole doses were uptitrated to achieve normal prolactin (PRL) levels, restore menses, and eliminate galactorrhea. ...During treatment, menses resumed in 67% of amenorrheic patients; galactorrhea resolved in 67%. Mild adverse effects were reported in 92% …
Ropinirole doses were uptitrated to achieve normal prolactin (PRL) levels, restore menses, and eliminate galactorrhea. ...During trea …
Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson's disease - network meta-analysis.
Sako W, Kogo Y, Koebis M, Kita Y, Yamakage H, Ishida T, Hattori N. Sako W, et al. NPJ Parkinsons Dis. 2023 Oct 19;9(1):143. doi: 10.1038/s41531-023-00589-8. NPJ Parkinsons Dis. 2023. PMID: 37853009 Free PMC article.
According to the surface under the cumulative ranking curve (SUCRA) in the NMA, ropinirole transdermal patch (SUCRA, 0.861) ranked the highest in efficacy, followed by pramipexole (0.762), ropinirole extended release (ER) (0.750), and safinamide (0.691). In terms of …
According to the surface under the cumulative ranking curve (SUCRA) in the NMA, ropinirole transdermal patch (SUCRA, 0.861) ranked th …
428 results